Author: Kempf, Christoph; Stucki, Martin; Boschetti, Nicola
Title: Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins Cord-id: y1d0leic Document date: 2006_4_3
ID: y1d0leic
Snippet: Patients with immunodeficiencies or some types of autoimmune diseases rely on a safe therapy with intravenous immunoglobulins (IVIGs) manufactured from human plasma, the only available source for this therapeutic. Since plasma is predisposed to contamination by a variety of blood-borne pathogens, ascertaining and ensuring the pathogen safety of plasma-derived therapeutics is a priority among manufacturers. State-of-the-art manufacturing processes provide a high safety standard by incorporating v
Document: Patients with immunodeficiencies or some types of autoimmune diseases rely on a safe therapy with intravenous immunoglobulins (IVIGs) manufactured from human plasma, the only available source for this therapeutic. Since plasma is predisposed to contamination by a variety of blood-borne pathogens, ascertaining and ensuring the pathogen safety of plasma-derived therapeutics is a priority among manufacturers. State-of-the-art manufacturing processes provide a high safety standard by incorporating virus elimination procedures into the manufacturing process. Based on their mechanism these procedures are grouped into three classes: partitioning, inactivation, and virusfiltration.
Search related documents:
Co phrase search for related documents- acute respiratory syndrome and lod low detection limit: 1, 2, 3, 4
- acute respiratory syndrome and log inactivation: 1, 2, 3, 4
- acute respiratory syndrome and log reduction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38
- acute respiratory syndrome and log reduction factor: 1
- acute respiratory syndrome and long period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53
- acute respiratory syndrome and low biological activity: 1
- acute respiratory syndrome and low detection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61
- acute respiratory syndrome and low detection limit: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute respiratory syndrome and low ph treatment: 1
- lod low detection limit and low detection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- lod low detection limit and low detection limit: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- log inactivation and long period: 1
- log reduction and long period: 1, 2
- log reduction and lrf log reduction factor: 1
- log reduction factor and lrf log reduction factor: 1
Co phrase search for related documents, hyperlinks ordered by date